Artelo BiosciencesARTL
ARTL
About: Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Employees: 6
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
107% more capital invested
Capital invested by funds: $36.6K [Q4 2024] → $75.8K (+$39.2K) [Q1 2025]
33% more funds holding
Funds holding: 6 [Q4 2024] → 8 (+2) [Q1 2025]
1.57% more ownership
Funds ownership: 1.07% [Q4 2024] → 2.64% (+1.57%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$20
16%
downside
Avg. target
$20
16%
downside
High target
$20
16%
downside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 16%downside $20 | Buy Upgraded | 8 Jul 2025 |
Financial journalist opinion
Based on 5 articles about ARTL published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium
ART26.12, a Novel FABP5 Inhibitor, Demonstrates Sustained Analgesic Effects Without Tolerance ART26.12, a Novel FABP5 Inhibitor, Demonstrates Sustained Analgesic Effects Without Tolerance
Positive
Benzinga
3 days ago
Artelo Biosciences Analyst See It As An Emerging Biotech
Analyst Jason Kolbert upgrades Artelo to Buy with a new $20 price target citing multiple promising drug assets.
Neutral
GlobeNewsWire
4 days ago
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
ART12.11, the Patented CBD:TMP Cocrystal, Demonstrates Potent Antidepressant-Like Activity and Cognitive Benefits Over Leading SSRI
Neutral
GlobeNewsWire
1 week ago
Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market SOLANA BEACH, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced favorable results from its first-in-human study evaluating ART26.12, a novel inhibitor of Fatty Acid Binding Protein 5 (FABP5).
Neutral
GlobeNewsWire
2 weeks ago
Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing
SOLANA BEACH, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced it has entered into a definitive securities purchase agreement for an At-the-Market private placement for gross proceeds of approximately $1.425 million.
Neutral
GlobeNewsWire
1 month ago
Artelo Biosciences Announces Reverse Stock Split
SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that on May 20, 2025 Artelo's Board of Directors approved a 6-for-1 reverse stock split (“Reverse Split”) of the Company's common stock (“Common Stock”).
Neutral
GlobeNewsWire
1 month ago
Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study
SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 (https://bpsasm.org/) that further validates the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating osteoarthritis (OA) pain.
Neutral
GlobeNewsWire
1 month ago
New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression
SOLANA BEACH, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today welcomed the publication of a comprehensive review in Neurobiology of Disease, titled “Fatty acid binding proteins and their involvement in anxiety and mood disorders,” that underscores the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating mood and anxiety disorders.
Neutral
GlobeNewsWire
1 month ago
Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results
SOLANA BEACH, Caif., May 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended March 31, 2025.
Neutral
GlobeNewsWire
2 months ago
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis
ART26.12 Phase 1 in healthy volunteers completes enrollment with clinical data announcement expected this quarter ART26.12 Phase 1 in healthy volunteers completes enrollment with clinical data announcement expected this quarter
Charts implemented using Lightweight Charts™